Yearend | Nanologica

Nanologicas bokslutskommuniké 2022

10 February, 2023

FINANSIELL SAMMANFATTNING · Nettoomsättningen för fjärde kvartalet uppgick till 674 TSEK (676) och för helåret till 1 555 TSEK (12 914) · Rörelseresultatet för kvartalet uppgick till -13 251 TSEK (-14 108) och för helåret till -50 850 TSEK (-40 689) · Resultatet efter skatt för kvartalet uppgick till -14 855 TSEK (-15 222) och för helåret till -55 231 TSEK (-44 829) · Resultat per aktie före och efter utspädning var -0,42 SEK (-0,54)

Nanologica’s Interim Report Jan-Sep 2022

11 November, 2022

Report presentation Q3 2022 FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period to TSEK -37,599 (-26,581) Result after tax for the quarter amounted to TSEK -10,988 (-12,546) and for the nine-month period to TSEK -40,376 (-29,607) Earnings per share before and after dilution were

Nanologica’s Year-End Report 2021

8 February, 2022

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 676 (6,071) and for the full year to TSEK 12,914 (16,135) The operating result for the fourth quarter amounted to TSEK -14,108 (-3,648) and for the full year to TSEK -40,689 (-19,571) Result after tax for the fourth quarter amounted to TSEK -15,222 (-5,427) and for the full year to TSEK -44,829 (-22,199) Earnings per share before and after dilution were SEK -0,54 (-0,20)

Nanologicas bokslutskommuniké 2021

8 February, 2022

FINANSIELL SAMMANFATTNING · Nettoomsättningen för fjärde kvartalet uppgick till 676 TSEK (6 071) och för helåret till 12 914 TSEK (16 135) · Rörelseresultatet för kvartalet uppgick till -14 108 TSEK (-3 648) och för helåret till -40 689 TSEK (-19 571) · Resultatet efter skatt för kvartalet uppgick till -15 222 TSEK (-5 427) och för helåret till -44 829 TSEK (-22 199) · Resultat per aktie före och efter utspädning var -0,54 SEK (-0,20)

Year-End Report Nanologica 2020

26 February, 2021

SUMMARY OF THE PERIOD FINANCIAL OVERVIEW Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) Loss per share for the period was

Nanologicas bokslutskommuniké jan-dec 2019

7 February, 2020

FINANSIELL SAMMANFATTNING · Nettoomsättningen ökade till 10 227 TSEK (4 145), varav fjärde kvartalet 2 981 TSEK (2 276) · Rörelsens kostnader uppgick till -34 442 TSEK (-25 719), varav fjärde kvartalet -9 746 TSEK (-6 956) · Resultatet efter skatt uppgick till -19 588 TSEK (-20 889), varav fjärde kvartalet -6 226 TSEK (-4 578) · Resultat per aktie var -1,18 SEK (-1,80), varav fjärde kvartalet -0,37 SEK (-0,28) · Likvida medel uppgick på balansdagen

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.